OBJECTIVE: We report a case of thyrotoxic periodic paralysis (TPP) in a bodybuilder who developed paralysis secondary to thyrotoxicosis factitia (TF) after taking a supplement containing thyroid hormone. Interestingly, the patient had no intrinsic thyroid disease. Prompt recognition of thyrotoxicosis is critical to avoid progression of paralysis and subsequent complications. METHODS: We discuss a 27 year-old body builder who presented after a 3-day bodybuilding competition with sudden upper and lower extremity paralysis. He admitted to taking anabolic steroids, a supplement containing an unknown amount of thyroid hormone for two weeks, and furosemide 40 mg twice daily with near-complete fluid restriction for three days. RESULTS: Laboratory results showed a thyroid-stimulating hormone level of <0.010 mIU/L (0.3–5.8 uIU/mL), normal total T3 level, elevated free T4 level of 3.6 ng/dL (0.8–1.9 ng/mL), and potassium level of 1.9 mEq/L (3.7–5.2 mEq/L). Thyroid peroxidase antibody, thyroid stimulating immunoglobulin and thyroglobulin antibody levels were normal. Thyroid uptake was 1% (8–25%) after administration of I-123 and thyroglobulin level was 9 ng/mL (1.4 – 29.2 ng/mL). The patient was treated withnormal saline infusion, magnesium supplementation and a total of 230 mEq of potassium within 12 hours of hospitalization. Muscle weakness resolved within this time period and potassium level normalized. By the third day of hospitalization free thyroxine level also normalized and TSH improved to 0.1 mIU/L. CONCLUSION: TPP is a rare complication of thyrotoxicosis that should be considered in bodybuilders who are presenting with acute muscle weakness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.